Shire’s Motegrity: US FDA Panel Nod On CV Safety Comes With Concern About Neuropsych Events

In unanimously endorsing prucalopride for chronic idiopathic constipation, advisory committee seems reassured by extensive data on 5-HT4 agonist’s cardiovascular safety, but some members called for an epidemiological study to assess possible suicidality signal.

FDA Advisory Committee Feature image

Shire PLC’s constipation drug Motegrity (prucalopride) won a US FDA’s advisory committee’s unanimous endorsement Oct. 18 on the strength of reassuring cardiovascular safety data, although some panelists called for further evaluation of a potential suicidality signal.

The Gastrointestinal Drugs Advisory Committee voted 10-0 that prucalopride’s risk-benefit profile supports approval for treatment of chronic idiopathic constipation (CIC)....

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers